Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Estrogen receptor promoter methylation is an early marker for premalignant lesions
February 23rd, 2006
According to a study from Germany, methylation of estrogen receptor (ER) beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker for premalignant lesions. "The function of ER-beta in mammary tissue is not completely understood. While early observations were often conflicting, more recent data suggest an important role as a tumor-suppressor gene," wrote A. Rody and colleagues, University of Frankfurt. "A decrease of ER-beta expression has been observed in ductal carcinoma in situ and invasive carcinoma as compared with benign mammary epithelial cells. The loss of ER-beta resulted in abnormal...
Source: Women's Health Weekly (2006-02-23)
|
